Olarn Roengvoraphoj1, Chukwuka Eze2, Maximilian Niyazi2, Minglun Li2, Guido Hildebrandt3, Rainer Fietkau4, Claus Belka2, Farkhad Manapov2. 1. Department of Radiation Oncology, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany. Olarn.roengvoraphoj@med.uni-muenchen.de. 2. Department of Radiation Oncology, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany. 3. Department of Radiation Oncology, University of Rostock, Südring 75, 18059, Rostock, Germany. 4. Department of Radiation Oncology, University Hospital Erlangen, Maximiliansplatz 2, 91054, Erlangen, Germany.
Abstract
BACKGROUND: Previous studies have demonstrated that female gender could be a prognostic factor in limited-disease (LD) small-cell lung cancer (SCLC), but the correlation between patient gender and survival parameters remains unclear. PATIENTS AND METHODS: Data from 179 LD SCLC patients treated with definitive chemoradiotherapy (CRT) were reviewed. Influence of patient gender on time to progression (TTP), local control (LC), brain metastasis-free (BMFS), distant metastasis-free (DMFS) and overall survival (OS) was analysed. RESULTS: Definitive CRT was completed by 179 (110 men/69 women) patients. Of these, 68 (38%; 34 men/34 women) patients were treated in concurrent and 111 (62%; 76 men/35 women) in sequential mode. Prophylactic cranial irradiation (PCI) was subsequently applied in 70 (39%; 36 men/34 women) patients with partial or complete response after CRT. Median OS was 20 (95% confidence interval [CI] 10-22) and 14 (95% CI 10-18) months in female and male patients, respectively (p = 0.021). In subgroups defined by remission status (complete and partial response) after CRT, an OS benefit for females compared to males was also detected. There was no correlation between patient gender and TTP, LC or DMFS, and no difference in OS in the female and male subgroups treated with PCI. The incidence of metachronous brain metastases (BMs) in the male and female subgroups differed significantly (40/110 men vs. 18/69 women, p = 0.03). Also, mean BMFS was significantly longer in women (p = 0.023). Patient gender also significantly correlated with OS on multivariate analysis after adjustment for other prognostic factors (p = 0.04, HR 1.38, 95% CI 1.08-1.92). CONCLUSION: In this heterogeneous LD SCLC patient cohort treated with definitive CRT, female gender was significantly associated with longer BMFS and OS, as well as with a lower incidence of metachronous brain failure.
BACKGROUND: Previous studies have demonstrated that female gender could be a prognostic factor in limited-disease (LD) small-cell lung cancer (SCLC), but the correlation between patient gender and survival parameters remains unclear. PATIENTS AND METHODS: Data from 179 LD SCLCpatients treated with definitive chemoradiotherapy (CRT) were reviewed. Influence of patient gender on time to progression (TTP), local control (LC), brain metastasis-free (BMFS), distant metastasis-free (DMFS) and overall survival (OS) was analysed. RESULTS: Definitive CRT was completed by 179 (110 men/69 women) patients. Of these, 68 (38%; 34 men/34 women) patients were treated in concurrent and 111 (62%; 76 men/35 women) in sequential mode. Prophylactic cranial irradiation (PCI) was subsequently applied in 70 (39%; 36 men/34 women) patients with partial or complete response after CRT. Median OS was 20 (95% confidence interval [CI] 10-22) and 14 (95% CI 10-18) months in female and male patients, respectively (p = 0.021). In subgroups defined by remission status (complete and partial response) after CRT, an OS benefit for females compared to males was also detected. There was no correlation between patient gender and TTP, LC or DMFS, and no difference in OS in the female and male subgroups treated with PCI. The incidence of metachronous brain metastases (BMs) in the male and female subgroups differed significantly (40/110 men vs. 18/69 women, p = 0.03). Also, mean BMFS was significantly longer in women (p = 0.023). Patient gender also significantly correlated with OS on multivariate analysis after adjustment for other prognostic factors (p = 0.04, HR 1.38, 95% CI 1.08-1.92). CONCLUSION: In this heterogeneous LD SCLCpatient cohort treated with definitive CRT, female gender was significantly associated with longer BMFS and OS, as well as with a lower incidence of metachronous brain failure.
Authors: J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau Journal: N Engl J Med Date: 1992-12-03 Impact factor: 91.245
Authors: Daniel B Fried; David E Morris; Charles Poole; Julian G Rosenman; Jan S Halle; Frank C Detterbeck; Thomas A Hensing; Mark A Socinski Journal: J Clin Oncol Date: 2004-12-01 Impact factor: 44.544
Authors: A T Turrisi; K Kim; R Blum; W T Sause; R B Livingston; R Komaki; H Wagner; S Aisner; D H Johnson Journal: N Engl J Med Date: 1999-01-28 Impact factor: 91.245
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: N Murray; P Coy; J L Pater; I Hodson; A Arnold; B C Zee; D Payne; E C Kostashuk; W K Evans; P Dixon Journal: J Clin Oncol Date: 1993-02 Impact factor: 44.544
Authors: Brian E Lally; Ann M Geiger; James J Urbanic; Jerome M Butler; Stacy Wentworth; Michael C Perry; Lynn D Wilson; Janet K Horton; Frank C Detterbeck; Antonius A Miller; Charles R Thomas; A William Blackstock Journal: Lung Cancer Date: 2008-10-02 Impact factor: 5.705
Authors: Haiyan Zeng; Danyang Zheng; Willem J A Witlox; Antonin Levy; Alberto Traverso; Feng-Ming Spring Kong; Ruud Houben; Dirk K M De Ruysscher; Lizza E L Hendriks Journal: Front Oncol Date: 2022-06-10 Impact factor: 5.738